AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

IL-6 And IL-10 Critical In Primary But Not Secondary Infection.(Brief Article)

Vaccine Weekly

| June 20, 2001 | COPYRIGHT 2001 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2001 JUN 20 - (NewsRx.com & NewsRx.net) --

by N.R. Saltmarsh, staff medical writer - Interleukin (IL)-6 and IL-10 substantially decrease spleen viral loads following infection with Friend retrovirus (FV) but are less relevant in long-term infection or following vaccination, according to a new report in the Journal of General Virology.

"We investigated the role of the B-cell stimulating cytokines IL-5 and IL-6, and the immunosuppressive cytokine IL-10, during primary and secondary immune responses in mice against infection with Friend retrovirus (FV) (murine leukemia virus)," wrote B.D. Strestik and associates.

The researchers, from the University of Wurzburg, Germany, and the U.S. National Institute of Allergy and Infectious Diseases, found that IL-5(-/-) mice and C57BL/6 wild-type mice controlled the virus similarly well, but IL-6(-/-) and IL-10(-/-) mice carried enhanced viral loads in spleen cells during acute FV infection.

During chronic infection, however, deficiency of IL-6 or IL-10 became less relevant in control of FV, noted Strestik and colleagues.

Following vaccination with a live attenuated vaccine virus and subsequent challenge with FV, IL-5- and IL-6-deficient mice had significantly lower levels of virus-neutralizing immunoglobulin G antibodies, yet all three cytokine-deficient types of mice were protected, ...

Related articles from newspapers, magazines, journals, and more
Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV...
Press release article from: PR Newswire February 25, 2008 700+ words
...Instrumentation Laboratory (IL), a leading clinical...HemosIL(R) FII & FV assay as a European...beginning March 4th through IL, the exclusive worldwide...HemosIL FII & FV assay. Xpert HemosIL...HemosIL FII & FV test will complement IL's line of fully automated...
Cancer Immunotherapy "Preparation And Characterization Of A Humanized 520C9...
Newspaper article from: Immunotherapy Weekly October 12, 1998 700+ words
...Thus, targeting interleukin-2 (IL-2) to the tumour site should improve...encoding a humanized 520C9 single-chain Fv/human IL-2 fusion protein (H520C9sFv-hIL...protooncogene product, p 185, linked to human IL-2. H520C9sFv-hIL-2 was stably...
Cepheid Receives FDA Clearance for Xpert(R) HemosIL(R) FII & FV Test.
Press release article from: PR Newswire September 24, 2009 700+ words
...a partnership with IL, the exclusive worldwide...HemosIL FII & FV test. "The Xpert...GeneXpert System. IL is a leader in the...HemosIL FII & FV test will enable laboratories...HemosIL FII & FV is Cepheid's eighth...receive FDA clearance. IL has been exclusively...
Cepheid Receives FDA Clearance for Xpert[R] HemosIL[R] FII & FV Test.
Newspaper article from: Blood Weekly October 15, 2009 700+ words
...a partnership with IL, the exclusive worldwide...HemosIL FII & FV test (see also Thrombophilia...GeneXpert System. IL is a leader in the...HemosIL FII & FV test will enable laboratories...HemosIL FII & FV is Cepheid's eighth...receive FDA clearance. IL has been ...
Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test.
Newspaper article from: Blood Weekly June 18, 2009 700+ words
...Xpert HemosIL FII & FV delivers results in just...Instrumentation Laboratory (IL), the exclusive worldwide...Xpert HemosIL FII & FV test (see also Thrombophilia...Chief Executive Officer of IL. "In combination with...Xpert HemosIL FII & FV is the sixth GeneXpert...
Structural analysis of anti-HIV monoclonal antibody 447-52D Fv feasible.
Newspaper article from: Biotech Week August 6, 2003 700+ words
...monoclonal antibody 447-52D Fv is feasible, thanks to a novel...determination of the recombinant 447-52D Fv and its complex with V3 peptides...and isotope labeling of the Fv of the human HIV-1 neutralizing...Department of Structural Biology, IL-76100 Rehovot, Israel. The...
B-Cell Lymphoma "Treatment of B-Cell Lymphoma with Chimeric IgG and...
Newspaper article from: Gene Therapy Weekly October 19, 1998 700+ words
...trials. The combination of interleukin-2 (IL-2) can augment the therapeutic effect...was genetically modified to contain the IL-2 domain and thus use the unique targeting ability of Abs to direct IL-2 to the tumor site. Two forms of the...
Inhibitex Initiates Phase I Trial of FV-100 for the Treatment of Shingles.
Press release article from: Business Wire April 29, 2008 700+ words
...Continued Clinical Evaluation of Higher Doses of FV-100 on Track ATLANTA -- Inhibitex, Inc...Investigational New Drug application (IND) for FV-100, its oral nucleoside analogue in...of up to four single ascending doses of FV-100 in healthy subjects. Each dose cohort...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA